Red Light to support Carhart-Harris Lab for study

Executive Summary

• Red Light Holland Corp., through its subsidiary Filament Health Corp., has entered into a support agreement with the University of California, San Francisco (UCSF) to facilitate the Carhart-Harris Lab’s (CHL) global psychedelic study.
• Filament Health will provide participation instructions for the CHL study to all researchers and clinicians receiving Filament’s pharmaceutical-grade botanical psilocybin candidate, PEX010, including those in clinical trials and federally authorized compassionate use programs.
• The collaboration aims to gather real-world evidence on individual responses to psychedelics in naturalistic settings, leveraging Filament’s wide distribution network to access a diverse patient population.

Key Details

• Parties Involved: Red Light Holland Corp. (via Filament Health Corp.) and the University of California, San Francisco (UCSF) Carhart-Harris Lab (CHL).
• Product: Filament Health’s patented drug candidate, PEX010, a pharmaceutical-grade botanical psilocybin.
• Scope of Support: Filament will distribute instructions on how to participate in the CHL global psychedelic study to all recipients of PEX010.
• Target Audience for Distribution: Researchers and clinicians receiving PEX010, specifically those involved in clinical trials and federally authorized compassionate use programs.
• Study Details: The CHL global psychedelic study is a large-scale online research initiative led by Dr. Robin Carhart-Harris. It examines factors shaping individual responses to psychedelics in naturalistic settings and is open to anyone planning to take a psychedelic substance in any setting.
• Filament Health Track Record: PEX010 has been supplied to over 70 trials worldwide and authorized for use in several federally authorized compassionate use programs.
• Strategic Goal: To contribute real-world evidence to the global scientific understanding of botanical psilocybin, informing policy-makers and the medical community regarding legal, responsible accessibility.

Notable Quotes

• Todd Shapiro, CEO and Director of Red Light Holland: "Filament's wide distribution of PEX010 offers a unique opportunity for this study to gain access to a wider patient population... We are excited to help contribute real-world evidence to the global scientific understanding of botanical psilocybin, in the hope of informing both policy-makers and the medical community as we work toward increasing legal, responsible accessibility for patients who could benefit."
• Dr. Robin Carhart-Harris, UCSF: "The more diverse and representative our data, the stronger the science... Patients receiving legal access to psilocybin, especially under compassionate use, represent an important and understudied population. Their participation will help us build a clearer picture of how psychedelics work across different clinical and real-world contexts."